Table 1.
Comparison of baseline data between 2 groups.
| Group | Age (year) | tPSA (ng/mL) | fPSA (ng/mL) | PV (cm3) | F/T | PSAD (ng/mL/cm3) | (F/T)/PSAD | fPSA/PSAD |
|---|---|---|---|---|---|---|---|---|
| Prostate cancer (n=251) | 70 (63, 75) | 9.64 (6.11, 13.8) | 0.9 (0.5, 1.53) | 31.12 (23.20, 46.70) | 0.095 (0.064, 0.151) | 0.281 (0.168, 0.421) | 0.327 (0.166, 0.646) | 2.885 (1.738, 5.818) |
| Prostatic hyperplasia (n=409) | 74 (71, 77) | 8.83 (8.14, 9.52) | 2.35 (1.56, 3.04) | 93.51 (63.53, 119.22) | 0.221 (0.130, 0.302) | 0.025 (−0.124, 0.151) | 1.612 (0.821, 2.394) | 11.177 (6.888, 18.607) |
| Z | −1.011 | −5.317 | −4.690 | −13.800 | −10.388 | −14.487 | −14.672 | −14.244 |
| P | 0.312 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Median (interquartile range) was used to show the data and nonparametric test (Mann-Whitney U test) was used to compare data between prostate cancer group and prostatic hyperplasia group because of non-normal distribution. PSA – prostate specific antigen; fPSA – free PSA; tPSA – total PSA; PV – prostate volume; F/T – the ratio of fPSA to tPSA; PSAD – prostate specific antigen density.